331 related articles for article (PubMed ID: 26957305)
21. Glioma biology and molecular markers.
Cohen AL; Colman H
Cancer Treat Res; 2015; 163():15-30. PubMed ID: 25468223
[TBL] [Abstract][Full Text] [Related]
22. Cerebellar high-grade gliomas do not present the same molecular alterations as supratentorial high-grade gliomas and may show histone H3 gene mutations.
Tauziède-Espariat A; Saffroy R; Pagès M; Pallud J; Legrand L; Besnard A; Lacombe J; Lot G; Borha A; Tazi S; Adle-Biassette H; Polivka M; Lechapt E; Varlet P
Clin Neuropathol; 2018; 37(5):209-216. PubMed ID: 29809131
[TBL] [Abstract][Full Text] [Related]
23. Tectal glioma as a distinct diagnostic entity: a comprehensive clinical, imaging, histologic and molecular analysis.
Liu APY; Harreld JH; Jacola LM; Gero M; Acharya S; Ghazwani Y; Wu S; Li X; Klimo P; Gajjar A; Chiang J; Qaddoumi I
Acta Neuropathol Commun; 2018 Sep; 6(1):101. PubMed ID: 30253793
[TBL] [Abstract][Full Text] [Related]
24. Application of multiplex ligation-dependent probe amplification (MLPA) and low pass whole genome sequencing (LP-WGS) to the classification / characterisation of low grade glioneuronal tumours.
Dyke J; Calapre L; Beasley A; Gray E; Allcock R; Bentel J
Pathol Res Pract; 2022 Jan; 229():153724. PubMed ID: 34942511
[TBL] [Abstract][Full Text] [Related]
25. [Classification of gliomas. Current progress and perspectives].
Capper D; Reifenberger G
Nervenarzt; 2015 Jun; 86(6):672, 674-6, 678-80, passim. PubMed ID: 25989737
[TBL] [Abstract][Full Text] [Related]
26. Serum levels of GFAP and EGFR in primary and recurrent high-grade gliomas: correlation to tumor volume, molecular markers, and progression-free survival.
Kiviniemi A; Gardberg M; Frantzén J; Parkkola R; Vuorinen V; Pesola M; Minn H
J Neurooncol; 2015 Sep; 124(2):237-45. PubMed ID: 26033547
[TBL] [Abstract][Full Text] [Related]
27. Progress in the application of molecular biomarkers in gliomas.
Wang J; Su HK; Zhao HF; Chen ZP; To SS
Biochem Biophys Res Commun; 2015 Sep; 465(1):1-4. PubMed ID: 26253473
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology.
Hatae R; Hata N; Suzuki SO; Yoshimoto K; Kuga D; Murata H; Akagi Y; Sangatsuda Y; Iwaki T; Mizoguchi M; Iihara K
Neuropathology; 2017 Jun; 37(3):191-199. PubMed ID: 27792249
[TBL] [Abstract][Full Text] [Related]
29. The genetic landscape of gliomas arising after therapeutic radiation.
López GY; Van Ziffle J; Onodera C; Grenert JP; Yeh I; Bastian BC; Clarke J; Oberheim Bush NA; Taylor J; Chang S; Butowski N; Banerjee A; Mueller S; Kline C; Torkildson J; Samuel D; Siongco A; Raffel C; Gupta N; Kunwar S; Mummaneni P; Aghi M; Theodosopoulos P; Berger M; Phillips JJ; Pekmezci M; Tihan T; Bollen AW; Perry A; Solomon DA
Acta Neuropathol; 2019 Jan; 137(1):139-150. PubMed ID: 30196423
[TBL] [Abstract][Full Text] [Related]
30. Genetic analysis to complement histopathological diagnosis of brain tumors.
Nakamura M; Shimada K; Ishida E; Nakase H; Konishi N
Histol Histopathol; 2007 Mar; 22(3):327-35. PubMed ID: 17163407
[TBL] [Abstract][Full Text] [Related]
31. FGF2 as a potential prognostic biomarker for proneural glioma patients.
Sooman L; Freyhult E; Jaiswal A; Navani S; Edqvist PH; Pontén F; Tchougounova E; Smits A; Elsir T; Gullbo J; Lennartsson J; Bergqvist M; Ekman S
Acta Oncol; 2015 Mar; 54(3):385-94. PubMed ID: 25263081
[TBL] [Abstract][Full Text] [Related]
32. Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20.
Marucci G; Morandi L; Magrini E; Farnedi A; Franceschi E; Miglio R; Calò D; Pession A; Foschini MP; Eusebi V
Virchows Arch; 2008 Dec; 453(6):599-609. PubMed ID: 18953566
[TBL] [Abstract][Full Text] [Related]
33. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas.
Idbaih A; Marie Y; Lucchesi C; Pierron G; Manié E; Raynal V; Mosseri V; Hoang-Xuan K; Kujas M; Brito I; Mokhtari K; Sanson M; Barillot E; Aurias A; Delattre JY; Delattre O
Int J Cancer; 2008 Apr; 122(8):1778-86. PubMed ID: 18076069
[TBL] [Abstract][Full Text] [Related]
34. Molecular diagnostics of gliomas: the clinical perspective.
Tabatabai G; Stupp R; van den Bent MJ; Hegi ME; Tonn JC; Wick W; Weller M
Acta Neuropathol; 2010 Nov; 120(5):585-92. PubMed ID: 20862485
[TBL] [Abstract][Full Text] [Related]
35. O6-methylguanine DNA methyltransferase gene promoter methylation status in gliomas and its correlation with other molecular alterations: first Indian report with review of challenges for use in customized treatment.
Jha P; Suri V; Jain A; Sharma MC; Pathak P; Jha P; Srivastava A; Suri A; Gupta D; Chosdol K; Chattopadhyay P; Sarkar C
Neurosurgery; 2010 Dec; 67(6):1681-91. PubMed ID: 21107199
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic and prognostic value of alpha internexin expression in a series of 409 gliomas.
Ducray F; Mokhtari K; Crinière E; Idbaih A; Marie Y; Dehais C; Paris S; Carpentier C; Dieme MJ; Adam C; Hoang-Xuan K; Duyckaerts C; Delattre JY; Sanson M
Eur J Cancer; 2011 Mar; 47(5):802-8. PubMed ID: 21194923
[TBL] [Abstract][Full Text] [Related]
37. [Glial and glioneuronal tumors in adults and children: main genetic alterations and towards a histomolecular classification].
Figarella-Branger D; Chappe C; Padovani L; Mercurio S; Colin C; Forest F; Bouvier C
Bull Cancer; 2013; 100(7-8):715-26. PubMed ID: 23831947
[TBL] [Abstract][Full Text] [Related]
38. Pathological significance of epidermal growth factor receptor expression and amplification in human gliomas.
Zhao LL; Xu KL; Wang SW; Hu BL; Chen LR
Histopathology; 2012 Oct; 61(4):726-36. PubMed ID: 22978472
[TBL] [Abstract][Full Text] [Related]
39. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
[TBL] [Abstract][Full Text] [Related]
40. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
Hartmann C; Hentschel B; Wick W; Capper D; Felsberg J; Simon M; Westphal M; Schackert G; Meyermann R; Pietsch T; Reifenberger G; Weller M; Loeffler M; von Deimling A
Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
